NCT00707694

Brief Summary

We believe extreme longevity is due to specific genes which function to delay aging and prevent disease. The purpose of the research is to identify the genes/mutations associated with healthier aging; to understand the biological functions of these genes/mutations; and to develop therapies to replicate these preservative genetic activities in individuals who do not have the genetic profile for longevity.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,000

participants targeted

Target at P75+ for all trials

Timeline
77mo left

Started Jul 1998

Longer than P75 for all trials

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress82%
Jul 1998Dec 2032

Study Start

First participant enrolled

July 1, 1998

Completed
10 years until next milestone

First Submitted

Initial submission to the registry

June 27, 2008

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 1, 2008

Completed
24.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2032

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2032

Last Updated

January 2, 2026

Status Verified

December 1, 2025

Enrollment Period

34.4 years

First QC Date

June 27, 2008

Last Update Submit

December 30, 2025

Conditions

Extreme Longevity

Keywords

95 years of age and older

Study Arms (3)

Probands

Ashkenazi Jews ages 95 and older

Offspring

Ashkenazi Jewish offspring of Ashkenazi Jewish parent(s) who lived to at least the age of 95

Controls

Ashkenazi Jewish people with no family history of longevity

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersYes
Age GroupsOlder Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Ashkenazi Jews: Ages 95 and older, their offspring and control group with no family history of longevity.

You may qualify if:

  • Ashkenazi Jewish, age 95+,
  • Offspring of person age 95+,
  • Offspring of parents who died age 70 or younger.

You may not qualify if:

  • Non-Ashkenazis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Private Homes

New York, New York, United States

RECRUITING

Hebrew Home Riverdale

Riverdale, New York, 10471, United States

RECRUITING

Related Publications (7)

  • DeVito LM, Barzilai N, Cuervo AM, Niedernhofer LJ, Milman S, Levine M, Promislow D, Ferrucci L, Kuchel GA, Mannick J, Justice J, Gonzales MM, Kirkland JL, Cohen P, Campisi J. Extending human healthspan and longevity: a symposium report. Ann N Y Acad Sci. 2022 Jan;1507(1):70-83. doi: 10.1111/nyas.14681. Epub 2021 Sep 8.

    PMID: 34498278RESULT

  • Moqri M, Herzog C, Poganik JR; Biomarkers of Aging Consortium; Justice J, Belsky DW, Higgins-Chen A, Moskalev A, Fuellen G, Cohen AA, Bautmans I, Widschwendter M, Ding J, Fleming A, Mannick J, Han JJ, Zhavoronkov A, Barzilai N, Kaeberlein M, Cummings S, Kennedy BK, Ferrucci L, Horvath S, Verdin E, Maier AB, Snyder MP, Sebastiano V, Gladyshev VN. Biomarkers of aging for the identification and evaluation of longevity interventions. Cell. 2023 Aug 31;186(18):3758-3775. doi: 10.1016/j.cell.2023.08.003.

    PMID: 37657418RESULT

  • Moqri M, Herzog C, Poganik JR, Ying K, Justice JN, Belsky DW, Higgins-Chen AT, Chen BH, Cohen AA, Fuellen G, Hagg S, Marioni RE, Widschwendter M, Fortney K, Fedichev PO, Zhavoronkov A, Barzilai N, Lasky-Su J, Kiel DP, Kennedy BK, Cummings S, Slagboom PE, Verdin E, Maier AB, Sebastiano V, Snyder MP, Gladyshev VN, Horvath S, Ferrucci L. Validation of biomarkers of aging. Nat Med. 2024 Feb;30(2):360-372. doi: 10.1038/s41591-023-02784-9. Epub 2024 Feb 14.

    PMID: 38355974RESULT

  • Bae H, Song Z, Ali A, Sasaki T, Tesi N, Lords H, Leshchyk A, Abe Y, Hirose N, Arai Y, Barzilai N, Weiss EF, Hulsman M, van der Lee S, van Schoor NM, Huisman M, Pijnenburg Y, van der Flier W, Reinders M, Holstege H, Milman S, Perls TT, Andersen SL, Sebastiani P. Increased genetic protection against Alzheimer's disease in centenarians. Geroscience. 2026 Apr;48(2):1815-1827. doi: 10.1007/s11357-025-01774-8. Epub 2025 Jul 4.

    PMID: 40615639RESULT

  • Ali A, Zhang ZD, Gao T, Aleksic S, Gavathiotis E, Barzilai N, Milman S. Identification of functional rare coding variants in IGF-1 gene in humans with exceptional longevity. Sci Rep. 2025 Mar 25;15(1):10199. doi: 10.1038/s41598-025-94094-y.

    PMID: 40133344RESULT

  • Ying K, Castro JP, Shindyapina AV, Tyshkovskiy A, Moqri M, Goeminne LJE, Milman S, Zhang ZD, Barzilai N, Gladyshev VN. Depletion of loss-of-function germline mutations in centenarians reveals longevity genes. Nat Commun. 2024 Oct 19;15(1):9030. doi: 10.1038/s41467-024-52967-2.

    PMID: 39424787RESULT

  • Barzilai N, Gabriely I, Atzmon G, Suh Y, Rothenberg D, Bergman A. Genetic studies reveal the role of the endocrine and metabolic systems in aging. J Clin Endocrinol Metab. 2010 Oct;95(10):4493-500. doi: 10.1210/jc.2010-0859.

    PMID: 20926537DERIVED

Study Officials

  • Nir Barzilai, MD

    Albert Einstein College of Medicine

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Tina Gao

CONTACT

718-839-7176tina.gao@einsteinmed.edu

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 27, 2008

First Posted

July 1, 2008

Study Start

July 1, 1998

Primary Completion (Estimated)

December 1, 2032

Study Completion (Estimated)

December 1, 2032

Last Updated

January 2, 2026

Record last verified: 2025-12

Locations

US(2)